newsfilter
← Latest News
GlobeNewswire·

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

  • Cogent Biosciences presented preclinical data on CGT1145, a selective JAK2 V617F inhibitor, at the 2026 EHA Congress in Stockholm.
  • CGT1145 demonstrates potential best-in-class properties with >100x selectivity over JAK2 WT and JAK1/3 isoforms compared to currently approved JAK inhibitors.
  • The inhibitor exhibits high oral bioavailability, low clearance across species, and the potential to eradicate JAK2 V617F MPN propagating cells while inducing molecular remission.
  • CGT1145 aims to address the underlying mutational driver of BCR-ABL-negative myeloproliferative neoplasms while mitigating off-target hematological effects.
  • The company remains on track to submit an Investigational New Drug (IND) application for CGT1145 in 2026.
  • JAK2 V617F is the most prevalent abnormality in BCR-ABL-negative MPNs, occurring in ~95% of polycythemia vera patients and 50% of primary myelofibrosis or essential thrombocythemia patients.
  • Poster details are available on the Cogent Biosciences website under the pipeline publications section.
  • Cogent's most advanced clinical program, bezuclastinib, targets the KIT D816V mutation for systemic mastocytosis and exon 17 mutations in advanced GIST.
  • The company is developing a portfolio of targeted therapies for mutations in ErbB2, PI3Ka, KRAS, and JAK2.